Visiongain Report Looks at Opportunities within the $1.8bn Acute Myeloid Leukaemia Market
Friday, December 6, 2019
- Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib
LONDON, Nov. 28, 2019 /PRNewswire/ -- The global acute myeloid leukaemia market is estimated to grow at a CAGR of 13% in the first half of the forecast period. In 2018, the chemotherapy segment held 32% share of the global acute myeloid leukaemia market.
http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 149-page report you will receive 143 charts- all unavailable elsewhere.
The 149-page Visiongain report provides clear detailed insight into the acute myeloid leukaemia market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
To request sample pages from this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/global-acute-myeloid-leukaemia-market-forecast-to-2029/#download_sampe_div
Report Scope
-- Global Acute Myeloid Leukaemia Market forecast to 2029
-- Forecast of the Global Acute Myeloid Leukaemia market by Treatment Type and Product Type: -- Chemotherapy: Cytarabine, Daunorubicin, Others -- Targeted Therapy: Midostaurin, Enasidenib, Others
-- This report provides individual revenue forecasts to 2029 for these regional and national markets: -- North America: US, Canada, and Mexico -- Europe: Germany, France, United Kingdom, Italy, Spain and rest of Europe -- Asia-Pacific: Japan, China, India, Australia and Rest of Asia-Pacific -- LAMEA: GCC, Brazil, South Africa, Rest of LAMEA
Each national market forecast is further segmented by type: chemotherapy and targeted therapy.
-- Our study discusses the selected leading companies that are the major players in the acute myeloid leukaemia market: -- Bristol-Myers Squibb Company -- Celgene -- Clavis Pharma ASA -- Daiichi Sankyo -- Eisai -- GSK -- Novartis -- Roche -- Sunesis Pharmaceuticals -- Teva
-- This report discusses factors that drive and restrain the acute myeloid leukaemia market. This report also discusses the opportunities that can be tapped in this market.
-- This report discusses Porter's Five Forces analysis of the acute myeloid leukaemia market.
-- This report also discusses several new agents that are in development for the treatment of acute myeloid leukaemia.
-- Key questions answered in this report: -- How is the Acute myeloid leukemia market evolving? -- What are the drivers and restraints for the growth of the acute myeloid leukemia market? -- What are the market shares of each segment of the overall acute myeloid leukemia market in 2019? -- How will each acute myeloid leukemia submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2029? -- How will the market shares for each acute myeloid leukemia submarket develop from 2019 to 2029? -- What is the value of the leading acute myeloid leukemia segments in important regions of the world? -- What will be the main driver for the overall market from 2019 to 2029? -- How will political and regulatory factors influence the regional markets and submarkets? -- How will the market shares of the national markets change by 2029 and which geographical region will lead the market by 2029? -- Who are the leading players and what are their prospects over the forecast period? -- How will the industry evolve during the period between 2019 and 2029?
To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/global-acute-myeloid-leukaemia-market-forecast-to-2029/
Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.com to discuss any customized research needs you may have.
Companies covered in the report include:
AbbVie Agios Pharmaceuticals, Inc. Ambit Biosciences Corporation Amgen Animas Corporation Astex B. Braun Melsungen AG Baxter, Becton, Dickinson and Company (BD) Bayer Boehringer Ingelheim Bristol-Myers Squibb Company (Bristol-Myers) Celator Pharmaceuticals, Inc. Celgene Clavis Pharma ASA (Clavis Pharma) Cyclacel Daiichi Pharmaceutical Daiichi Sankyo Eisai Co., Ltd. (Eisai) F. Hoffmann-La Roche Ltd. (Roche) Fresenius SE & Co. KGaA GlaxoSmithKline plc (GSK) GLOBOCAN Hospira Medtronic Moog Inc. NeoMed Norsk Hydro Novartis Onyx Pharmaceuticals Sankyo Seattle Genetics Smiths Group Plc., Sunesis Pharmaceuticals, Inc. (Sunesis) TEVA Pharmaceutical Industries Limited (TEVA)
List of Organizations Mentioned in the Report American Cancer Organization Baylor Scott and White Research Institute Benaroya Research Institute at Virginia Mason Beth Israel Deaconess Medical Center Breslin Cancer Center Center for Blood Disorders and Stem Cell Transplantation Charles A. Sammons Cancer Center Columbia University Medical Dana Farber Cancer Institute Duke Cancer Center European Commission Fred Hutchinson Cancer Research Center Health Canada Herbert Irving Comprehensive Cancer Center Institute of Hematology & Blood Diseases Hospital,Tianjin James Graham Brown Cancer Center Legacy Emanuel Hospital & Health Center Mary Babb Randolph Cancer Center Massachusetts general Hospital Mayo Clinic MD Anderson Cancer Center Medical College of Wisconsin Cancer Center Medizinische Klinik und Poliklinik I Memorial Sloan Kettering Cancer Center Michigan State University Nantes University Hospital National Cancer Institute New Jersey Hematology Oncology Associates Northwestern University Ochsner Medical Center Penn State Hershey Cancer Institute-Clinical Trials Office Perelman Center for Advanced Medicine Princess Margaret Hospital St. Francis Cancer Center St. Joseph Mercy Hospital St. Vincent's Comprehensive Cancer Center Swedish Cancer Institute The Gayle and Tom Benson Cancer Center The University of Hong Kong The University of Iowa The University of Texas MD Anderson Cancer Center Thomas Jefferson University U.S. Food and Drug Administration (FDA) UCLA Medical Center, Division of Hematology/Oncology University Hospital, Caen University of Kansas Cancer Center University of Kansas Medical Center Research Institute University of Kentucky University of Louisville University of Michigan Health System University of Pennsylvania University of Texas M.D. Anderson Cancer Center VA Caribbean Healthcare System Weill Cornell Medical College Weill Medical College of Cornell University West Virginia University World Health Organization (WHO)
To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com
Related reports:
Global Biosimilars and Follow-On Biologics Market 2019-2029
Global Protein Expression Market Forecast to 2029
Top 25 Biosimilar Drug Manufacturers 2019
Global Diagnostic Imaging Market Forecast 2019-2029
Global Oncology Pricing, Reimbursement & Market Access 2019-2029
View original content:http://www.prnewswire.com/news-releases/visiongain-report-looks-at-opportunities-within-the-1-8bn-acute-myeloid-leukaemia-market-300963957.html
SOURCE Visiongain
|
|
|
|
JND eDiscovery Receives National Law Journal Hall of Fame Award in Two Categories | Mar 28, 2024
|
|
Trip.com's Global 3.3 Promotion Sees Record Success in Asia and Europe | Mar 28, 2024
|
|
Europe Fibercos and Towercos Market Dynamics Report 2024: Lessons Learned and Key Takeaways for Telcos and Infrastructure Companies | Mar 28, 2024
|
|
China Non-Invasive Prenatal Testing Analysis Report 2024: Testing Volume 2018-2032 and Market Estimation Forecasts 2024-2032 with Focus on Mergers & Acquisitions, Collaborations, and Partnerships | Mar 28, 2024
|
|
Global Highly Potent API (Active Pharmaceutical Ingredient) Industry Research 2023-2033: Advancements in Containment Technologies, and Increasing Investment for Manufacturing Units | Mar 28, 2024
|
|
Exclusive Networks announces a major step in its growth strategy in APAC with NEXTGEN Group acquisition | Mar 28, 2024
|
|
United States Self-Monitoring Blood Glucose Devices Market Research 2023-2032: SMBG Devices and CGM Systems Surge - The Shift from Traditional Blood Glucose Meters | Mar 28, 2024
|
|
"Bleach: Brave Souls" Thousand-Year Blood War Zenith Summons: Reinforcements Featuring Meninas, Rangiku, and Yumichika Begins March 31 Alongside a Spring Festival Campaign | Mar 28, 2024
|
|
Evolution enters Delaware through Rush Street Interactive | Mar 28, 2024
|
|
IDTechEx Discusses the Sustainability of Electric Vehicle Fire Protection Materials | Mar 28, 2024
|
|
|